Meetings of the Food and Drug Administration’s vaccines advisory committee are never dull affairs. Drenched in data, maybe, but never dull.
And Tuesday’s meeting of the Vaccines and Related Biological Products Advisory Committee promises to hew to that tradition as the independent vaccine experts are asked to debate whether it is time to update Covid-19 vaccines.
It seems pretty evident the FDA wants to hear “Yes” when the committee is asked to conduct its sole vote on the question: Does the committee recommend inclusion of a SARS-CoV-2 Omicron component for Covid-19 booster vaccines in the United States?